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Abstract
Objectives—Radiofrequency ablation (RFA) of Barrett’s esophagus (BE) is safe and effective in
eradicating dysplasia and intestinal metaplasia and may reduce rates of esophageal
adenocarcinoma (EAC). We assessed rates of and risk factors for disease recurrence after
successful treatment of BE with RFA.
Methods—We performed a retrospective cohort study of patients who completed RFA for
dysplastic BE or intramucosal carcinoma (IMC), achieved complete eradication of dysplasia (CE-
D) or intestinal metaplasia (CE-IM), and underwent subsequent endoscopic surveillance at a single
center. Rates of disease recurrence and progression were determined. Patients with and without
recurrent disease were compared to determine risk factors for recurrence.
Results—262 subjects underwent RFA during the study period. Of these, 119 and 112 patients
were retained in endoscopic surveillance after CE-D and CE-IM, respectively. Median observation
time was 397 days (range: 54-1668 days). Eight patients (7% of those with CE-IM) had recurrent
disease after a median of 235 days (range 55-1124 days). Progression to IMC (n=1) or EAC (n=2)
occurred in 3 of these 8 patients, all of whom had pre-ablation high-grade dysplasia (HGD). Five
patients had recurrence of non-dysplastic BE (n=3), low-grade dysplasia (n=1), and HGD (n=1).
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During 155 patient-years of observation, recurrence occurred in 5.2%/year, and progression
occurred in 1.9%/year. No clinical characteristics were associated with disease recurrence.
Conclusions—In patients with BE and dysplasia or early cancer who achieved CE-IM, BE
recurred in ~5%/year. Patient characteristics did not predict recurrence. Subjects undergoing RFA
for dysplastic BE should be retained in endoscopic surveillance.
INTRODUCTION
Barrett’s esophagus (BE) affects 1-2% of the general population (1, 2), and is the precursor
lesion of esophageal adenocarcinoma (EAC), a cancer with a marked increase in incidence
over the past four decades (3-5). Endoscopic ablative therapy is frequently performed to
treat dysplastic BE with the aim of permanently eliminating dysplasia and intestinal
metaplasia (IM) to prevent neoplastic progression. Recent studies of radiofrequency ablation
(RFA) for BE with dysplasia have demonstrated that RFA is safe and effective, with low
complication rates, high rates of complete eradication of dysplasia (CE-D) and intestinal
metaplasia (CE-IM), and a potential decrease in progression to cancer (6-9).
While RFA safely and effectively eradicates dysplasia and IM, the durability of the
neosquamous epithelium that regenerates is not well understood. This is especially true of
subjects with the most severe disease, those with high-grade dysplasia (HGD), and those
with intramucosal adenocarcinoma (IMC). The few studies that report on the durability of
successful response to treatment with RFA are limited by small sample sizes and short
periods of follow-up (10-15). A recent multicenter, randomized, sham-controlled trial
reported on the durability of RFA in dysplastic BE and found that dysplasia remained
eradicated in >85% of patients and IM in >75% of patients after 3 years, without RFA re-
treatment (16). However, only 54 of the 106 subjects in this trial had HGD; the remainder
had low-grade dysplasia (LGD).
The aim of this study was to determine rates of disease recurrence and progression following
successful eradication of dysplasia and IM in BE with dysplasia or IMC following RFA
therapy. We also sought to determine factors associated with disease recurrence following
CE-IM.
METHODS
Patient eligibility and data collection
We performed a retrospective study of adult patients who completed RFA therapy for BE
with LGD, HGD, or IMC and underwent subsequent endoscopic surveillance at University
of North Carolina (UNC) Hospitals between 2006 and 2011. Subjects who received an upper
endoscopy (EGD) with RFA between January 1, 2006 and November 1, 2011, were
identified by review of our electronic endoscopic database (Provation MD, Wolters Kluwer,
Minneapolis, MN). One of two investigators (HK, WB) then reviewed each subject using
the electronic medical record (WebCIS, UNC Health Care System) to determine eligibility
for inclusion. All institutional health information and imported external records were
abstracted. Patients were excluded if they never had treatment with RFA; were treated with
RFA for a non-BE-related disease; did not have a pre-ablation histology of LGD, HGD or
IMC; did not complete RFA therapy; or did not enter surveillance at UNC Hospitals with
CE-D or CE-IM. Patients were considered to be under surveillance if they received at least 1
EGD after a post-RFA EGD demonstrated CE-D or CE-IM. All eligible patients were
included in the surveillance cohort and were examined to determine durability of response to
RFA treatment.
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Pertinent data were extracted from clinical, endoscopy, and pathology reports for each
subject and included demographic information (age, gender, race, body mass index),
pertinent medical history (erosive esophagitis, peptic stricture), substance use (alcohol,
tobacco), medication use (anti-secretory therapy, non-steroidal anti-inflammatory drugs),
EGD findings (length of BE, hiatus hernia, erosions, ulcers, nodules), pre-ablation histology,
treatment provided, ablation outcomes, and durability outcomes.
Pre-treatment evaluation and procedural protocol
All patients had an initial consultation visit to discuss BE and dysplasia, its risk of
progression to cancer, and the risks and benefits of different treatment options including
continued endoscopic surveillance, ablative therapy, and, in the case of HGD or IMC,
esophagectomy. Prior to the first visit, the worst histologic grade of BE was determined by
review of original pathology records. An expert gastrointestinal pathologist reviewed all
cases, and if findings between the initial pathology report and the secondary review were
discordant, an additional expert gastrointestinal pathologist reviewed the case with
histologic classification by consensus.
Patients with BE and LGD were offered RFA followed by endoscopic surveillance, or
endoscopic surveillance alone. Patients with BE and HGD or IMC were offered RFA
followed by endoscopic surveillance, esophagectomy, or, in the case of HGD, endoscopic
surveillance alone. Patients with BE and HGD or IMC who opted for RFA had pre-treatment
staging by EGD and endoscopic ultrasound to exclude invasive disease (submucosal
infiltration, lymph node or metastatic spread) that would preclude curative endoscopic
treatment. If the BE segment contained nodularity, endoscopic mucosal resection (EMR)
was performed prior to beginning RFA therapy. Nodules were defined endoscopically as any
contoured irregularity and elevation of the mucosa without breaks, including Paris
classification 0-I and 0-IIa lesions (17). All resections were performed using either the
Olympus 18 mm oblique cap kit (Olympus America, Center Valley, PA) or the Duette
device (Cook Medical, Winston-Salem, NC). EMR performed with the Olympus device was
preceded by submucosal injection of saline, while EMR with the Duette device was
performed without prior injection. If the BE segment was not nodular, RFA was performed
as outlined below. RFA therapy was initiated two months after all nodular lesions were
removed by EMR, and if pathology specimens did not reveal submucosal infiltration of
EAC. Twice daily proton pump inhibitor therapy was prescribed to all patients prior to and
throughout RFA treatment.
Radiofrequency ablation was performed using the HALO360 device (BARRX Medical,
Sunnyvale, CA) for circumferential disease and the HALO90 device for focal lesions.
Standard procedural technique was used as previously described (8). Patients returned every
two months for repeat EGD to assess treatment response. EMR was performed if patients
developed nodular disease during the treatment period. Patients with non-nodular residual
disease underwent focal RFA treatment. Treatment was continued in this manner until no
visible BE was observed on white-light and narrow band imaging endoscopy. At this point,
treatment was considered complete and four-quadrant biopsies were taken from just distal to
the gastroesophageal junction and at 1 cm intervals along the length of the original BE
segment. Subjects were then offered continued endoscopic surveillance to monitor their
condition, either at our institution, or, for those not living locally, follow-up with their
referring gastroenterologist.
The date of these esophageal biopsies marked the “index date,” the date when the
surveillance period began. Surveillance EGDs at our institution were performed using
narrow band imaging and four-quadrant biopsies just distal to the gastroesophageal junction
and at 1 cm intervals along the length of the original BE segment. Separate biopsy samples
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were obtained for any visible BE during surveillance. Patients who had pre-ablation LGD
received surveillance EGDs every 6 months for one year, and if patients were disease-free
after one year, they were followed-up annually thereafter. From 2006-2009, patients who
had pre-ablation HGD or IMC received surveillance EGDs every 3 months for one year,
then every 6 months for the second year, and were followed-up annually thereafter. From
2009 to the present, any patient who achieved CE-IM received surveillance EGDs every 6
months for one year and then yearly, regardless of baseline histology. Physicians and
patients may have deviated from the surveillance protocol depending on individual clinical
considerations. No further RFA treatments were administered unless patients experienced
disease recurrence, at which point RFA re-treatment was considered.
Outcomes and statistical analysis
Upon completion of therapy, all biopsy specimens were analyzed by an expert
gastrointestinal pathologist to assess for the presence of residual BE and degree of dysplasia.
Any reading of dysplasia was subsequently confirmed by a second histological analysis by
an expert gastrointestinal pathologist. Outcomes upon treatment completion included CE-D
and CE-IM. CE-D was defined as the absence of dysplasia from all esophageal biopsies, and
CE-IM was defined as complete endoscopic resolution with the absence of IM from all
esophageal biopsies. Throughout the surveillance period, biopsy specimens were similarly
examined to determine the presence of any recurrent IM or dysplasia.
Two separate cohorts were analyzed: patients that achieved CE-D (with or without CE-IM)
and the subset of patients that achieved CE-IM. Primary durability outcomes included
recurrent disease and progressive disease. For the CE-IM cohort, recurrent disease was
defined as any recurrence of IM with or without dysplasia. For the CE-D cohort, recurrent
disease was defined as recurrence of any grade of dysplasia, not including non-dysplastic
(ND) BE. Progressive disease was defined as recurrence at a worse level than pre-treatment
histology. As patients actively under surveillance are scheduled to undergo EGD at least
yearly, those who had not undergone an EGD within the 15 months prior to the conclusion
of this study were considered lost to follow-up. The characteristics and clinical courses of
each patient with recurrent disease were described.
Statistical analysis was performed using Stata software (version 12.0; StataCorp LP, College
Station, TX). Descriptive statistics were performed for patients entering the surveillance
period upon achieving CE-IM. Categorical variables were reported as counts and
percentages. Continuous variables were reported as means and standard deviations or
medians and interquartile ranges for non-normally-distributed variables. Comparisons
between groups were performed using Fisher’s exact test for categorical variables and
Student’s t-test or Wilcoxon rank-sum test for continuous variables. Kaplan-Meier survival
analyses were performed to determine the rates of disease recurrence. For these Kaplan-
Meier analyses of dysplasia-free and intestinal metaplasia-free survival, any recurrent
dysplasia or IM, respectively, was considered a failure, even if subsequent RFA resulted in a
recurrent complete eradication. Comparisons between rates were performed using the log-
rank test. The UNC Institutional Review Board approved this study.
RESULTS
In all, 262 patients received RFA for BE during the study period. Of these, 244 had a pre-
treatment diagnosis of either dysplastic BE or IMC. Of 188 patients who completed
treatment for BE with dysplasia or IMC, 183 achieved CE-D, and 168 achieved CE-IM
(Figure 1). Within these groups, 119 and 112 patients entered endoscopic surveillance,
respectively, at our institution, with the remainder opting to undergo surveillance with their
local gastroenterologist due to proximity. Subjects returning to their referring
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gastroenterologist for surveillance were not significantly different from those pursuing
surveillance at UNC with respect to demographics or pre-treatment histology. Baseline
characteristics of the 112 patients who achieved CE-IM and underwent surveillance are
reported in Table 1. The mean age was 64.1 ± 10.9 years, 79.5% were male, 111 of the 112
(99.1%) patients were Caucasian, and the mean length of BE was 4 cm. Patients with IMC
were more likely to have had pre-ablation erosive esophagitis or to have received EMR at
any time. Patients underwent a mean of 3.0 ± 1.5 RFA sessions, and 63.4% received
circumferential therapy. Patients were followed in surveillance for a median of 397 days
(range 54-1668). Five patients were lost to follow-up.
In those under endoscopic surveillance following CE-D and CE-IM, an analysis of durability
was performed using Kaplan-Meier estimation. As demonstrated in Figure 2A, of the 119
patients who attained CE-D and enrolled in endoscopic surveillance at our institution, 85%
of patients remained free of dysplasia at a median follow-up of 393 days with no additional
therapy. Dysplasia did not recur in any subject treated for LGD; in those treated for HGD or
IMC, dysplasia recurred in 4.2% per year (Figure 2B), with a median time to recurrence of
173 days. All 5 recurrences of dysplasia were among those who had achieved CE-IM with
RFA. Of the 112 patients followed after CE-IM, 80% remained free of IM (Figure 3A).
Only 1 patient with pre-ablation LGD had recurrent IM (2.4% per year); whereas 5 with pre-
ablation HGD and 2 with pre-ablation IMC had recurrent IM (5.5% per year and 9.4% per
year, respectively) (Figure 3B). Among patients experiencing IM recurrence, IM recurred at
a median of 235 days into surveillance (range 55-1124).
Among the 8 patients who experienced recurrence of IM following CE-IM, most had a
benign clinical course (Table 2). In 5 of these patients, the histologic grade at the time of
recurrence was at or below the pre-treatment grade. Of these, 3 had histologic recurrence,
but no endoscopic evidence of recurrent BE. One of the other 2 patients had an “irregular z-
line” only, and the other had a small isolated island of BE. In all of these cases, the
pathologist described the histologic recurrence as “sparse,” “minute,” or within “one
fragment”. In no case was the recurrent BE noted to be sub-squamous. Three of the 8
patients experiencing recurrence of IM were re-treated with RFA for NDBE (n=1), LGD
(n=1), and HGD (n=1), and all subsequently had CE-IM. The two other patients who
experienced recurrence but not progression had NDBE at recurrence and continued
endoscopic surveillance.
All 3 patients who had histologic progression (i.e. grade at the time of recurrence greater
than the pre-treatment grade) had pre-treatment HGD. One developed a single, visible, 5
mm island of IMC, which was successfully treated with EMR. Another developed IMC
within an endoscopically normal-appearing gastroesophageal junction and shortly thereafter
progressed to EAC, which was subsequently treated successfully with esophagectomy. One
had an acute MI just prior to his scheduled yearly endoscopy, which was therefore
cancelled. He became symptomatic from a fungating esophageal mass 20 months after his
prior negative endoscopy and was subsequently diagnosed with metastatic EAC. He died
after systemic chemotherapy and radiation. During 155 total years of observation, the rate of
any recurrence was 5.2% per year, the rate of recurrence with HGD or worse histology was
2.6% per year, the rate of recurrence with EAC was 1.3% per year, and the rate of death
from EAC was 0.6% per year.
In bivariate analyses, we assessed a variety of clinical, endoscopic, and treatment variables
as predictors of recurrence following CE-IM. Patients with recurrence of IM were not
statistically different in these characteristics from those who did not recur in bivariate
analysis (Table 3). However, numerically, patients with recurrence were younger, with a
higher BMI, and with a longer BE length. They were also more likely to have had an
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esophageal stricture, erosive esophagitis, a medium or larger hiatal hernia, and a pre-ablation
histology of IMC. Multivariate analysis could not be performed due to the small number of
recurrences.
DISCUSSION
Endoscopic RFA is an established safe and effective therapy for dysplastic BE and results in
a high proportion of CE-D and CE-IM. However, the durability of CE-IM following
treatment, especially for subjects with more severe disease (HGD and IMC), is not clear.
This study demonstrates that the majority of patients successfully treated with RFA for
dysplastic BE or IMC maintain CE-IM after more than a year of follow-up. Of those who
developed recurrent IM, most were not histologically worse than the pre-treatment grade,
and the area of recurrence was generally small. More than half were in the setting of an
endoscopically normal-appearing esophagus or irregular z-line.
This study is the largest to date reporting RFA outcomes and durability in subjects with
HGD and IMC. However, several studies have examined the risk of IM recurrence following
successful RFA for dysplastic BE (Table 4). Pouw et al. demonstrated that among 43
patients who achieved CE-IM following RFA for HGD or early cancer, 5 (12%) had
histologic recurrence immediately distal to a normal-appearing neosquamous columnar
junction during a median follow-up of 21 months (10). Only 1 had endoscopic recurrence,
and none had recurrent dysplasia. In 2 series, Gondrie et al. reported no visible recurrence
among 23 patients with CE-IM following RFA for dysplastic BE (18, 19). One patient had
recurrence of focal IM just distal to the neosquamous columnar junction. In a multicenter
trial of RFA for HGD or early cancer, 23 of 24 patients achieved CE-IM with EMR and
RFA (12). Twenty-three of these patients received EMR prior to RFA, and 2 required
salvage EMR after RFA in order to obtain CE-IM. Only 3 patients (13%) who achieved CE-
IM had recurrence of IM at 22 months of median follow-up. Again, there was no recurrent
dysplasia. The same group reported 2 endoscopic and 3 histologic recurrences without
dysplasia among 19 patients (26%) who achieved CE-IM after RFA of BE segments ≥ 10
cm (13). Mean follow-up was 21 months after treatment completion. In a randomized trial of
RFA versus EMR for HGD or early cancer, none of 21 patients who had achieved CE-IM
had endoscopic recurrence after a median 15 months of follow-up (14). Four patients had
histologic recurrence without dysplasia at the neosquamous columnar junction. Two of these
were within single biopsy specimens and were not reproduced on subsequent endoscopies.
Vaccaro et al. reported recurrent IM in 15 of 47 patients (32%) who had achieved CE-IM
following RFA at a single center (15). Median follow-up in this study was 13.3 months.
Four of these recurrences had dysplasia (2 LGD and 2 HGD) at the neosquamous columnar
junction, none of which were seen endoscopically, and 1 represented progression from LGD
to HGD. In bivariate analysis, a longer baseline BE segment was associated with IM
recurrence. Three-year follow-up of a randomized controlled trial of RFA for dysplastic BE
showed recurrent IM in 14 of 108 patients who achieved CE-IM (16). Seven of the 14 had
recurrence at a normal or irregular z-line. The other 7 consisted of small, isolated islands
(n=3) or tongues (n=4). Among the patients with recurrence, only 3.8% of biopsies
demonstrated IM.
This study compares favorably with prior studies in that ≥ 80% were able to maintain CE-D
and CE-IM without additional therapy. Moreover, the recurrence rate of 5.2% per year is
lower than the calculated rates for the previous studies (Table 4). As in the other studies,
recurrence was typically minimal, with little endoscopic evidence of recurrence and few
positive biopsies in most cases. In addition, the majority of patients with recurrent IM had
uneventful clinical courses. Six (75%) of our recurrences were successfully re-treated
endoscopically or kept under surveillance. Nevertheless, despite our overall good outcomes,
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1 patient required esophagectomy after progressing to EAC, and 1 progressed to metastatic
EAC. The former patient had a large hiatal hernia but no endoscopic evidence of recurrence
despite the IMC seen histologically at the gastroesophageal junction. As described above,
the latter patient missed surveillance endoscopy due to a cardiac event, but the prior
surveillance endoscopy (20 months before his diagnosis of metastatic EAC) showed a
normal z-line without histologic abnormality. These two patients each had 9cm of pre-
ablation IM (90th percentile), but were otherwise without specific features in their pre-
recurrence clinical course that would distinguish them from the remainder of the cohort.
Cases such as these reinforce the need for continued surveillance in this patient population.
As suggested by Vaccaro et al. (15), the neosquamous columnar junction may be an area at
risk for the development of dysplasia or adenocarcinoma. However, the optimal method to
prevent such progression is not clear.
Due to the small number of recurrences, we were unable to determine predictors of
recurrence or progression. However, the median pre-RFA BE length was numerically
greater among those who had recurrence (7 vs. 4 cm, p=0.2). Furthermore, the two patients
who progressed to EAC had among the longest BE segments in the cohort. Vaccaro et al.
found that the baseline BE length was significantly longer in those who developed
recurrence (15). The reasons for such an association are unclear, but longer length may be a
marker of more severe reflux, or may be a surrogate measure of the likelihood of harboring a
more genetically advanced dysplastic clone. There does not appear to be an increased risk of
the recurrence for patients who achieve CE-D without CE-IM, as none were seen in this
study. However, the small number of patients in this group (n=7) prevents a firm conclusion
on this matter. Larger studies are needed to identify predictors of recurrence, which would
be valuable to risk stratify patients after ablation in order to better target surveillance efforts.
This study has several limitations. As with other studies on this topic, sampling error is a
concern. Although this cohort was found to have CE-IM on biopsy, it is conceivable that
residual IM (especially sub-squamous or “buried” IM) might be missed and that patients
who never achieved true CE-IM were included in the cohort due to sampling error. In such
an instance, subsequent biopsies showing IM would incorrectly classify a patient as
recurrent disease when they should have been considered an incomplete initial treatment.
Such an error would have the effect of inflating our cohort size at the cost of increasing the
recurrence rate. One-third of patients who achieved CE-IM returned to their referring
physician for surveillance after treatment completion and were therefore not available for
follow-up. A difference in recurrence rate between this group and our cohort would bias our
recurrence estimate. However, the pretreatment histology of those receiving follow-up
locally was not different from those continuing at our institution, decreasing the concern that
baseline differences between the groups might lead to a biased estimate of disease
recurrence. Additionally, it is common that recurrence in this group prompts re-referral to
our center for management. Therefore, if such a bias exists, it likely results in an over-
estimate of recurrence. Given that this is a single-center study, the generalizability of our
findings, especially to practice settings with lower volumes of cases, is unclear. It should be
noted, however, that similar results have been reported in a cohort of subjects treated in
community practice (7). Other limitations of this study include the small number of
recurrences that prevents identification of predictors of recurrence, as well as its
retrospective nature.
In this study of patients with CE-IM following RFA of dysplastic BE, we found a low rate
of IM and dysplasia recurrence. Among those with recurrent IM, most had a benign course,
although three cases exhibited progressive disease. One subject, who was unable to attend
surveillance endoscopy, developed and died from metastatic esophageal adenocarcinoma.
Due to the small number of recurrences, we did not identify any statistically significant
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predictors of recurrence. In general, these results should serve to reassure patients and their
physicians that, in most cases, RFA induces a durable complete eradication of dysplasia and
intestinal metaplasia. At the same time, the few cases of progression point to the need for
continued surveillance following treatment. Further follow-up of this cohort and others is
needed to identify predictors of IM recurrence so that continued surveillance can be
appropriately targeted to the highest risk patients.
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WHAT IS CURRENT KNOWLEDGE
• Radiofrequency ablation (RFA) of dysplastic Barrett’s esophagus (BE) safely
and effectively eradicates dysplasia and intestinal metaplasia and reduces
progression to cancer.
• The durability of treatment-induced eradication of intestinal metaplasia is not
well understood.
• Risk factors for recurrence of intestinal metaplasia following ablation are
unknown.
WHAT IS NEW HERE
• In this cohort of patients who completed RFA for dysplastic BE, recurrence of
intestinal metaplasia after complete eradication occurred in 5.2% per year.
• Most patients with recurrence had a benign clinical course.
• Progression of disease occurred in 1.9% per year with associated morbidity and
mortality.
• No clinical characteristics were associated with disease recurrence.
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Flow diagram of patients treated for BE with RFA.
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Kaplan-Meier plots of dysplasia recurrence among patients who achieved CE-D after RFA,
overall (A) and grouped by pre-treatment histology (B). P-value based on log-rank test.
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Kaplan-Meier plot of IM recurrence among patients who achieved CE-IM after RFA, overall
(A) and grouped by pre-treatment histology (B). P-value based on log-rank test.
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Table 1
Baseline Characteristics of Patients Under Endoscopic Surveillance Following CE-IM
Characteristic Overall LGD HGD IMC p-value
N (%) 112 (100.0) 24 (21.4) 71 (63.4) 17 (15.2)
Age, years, mean (SD) 64.1 (10.9) 59.2 (12.3) 64.6 (9.6) 68.7 (11.8) 0.26
Male, n (%) 89 (79.5) 16 (66.7) 60 (84.5) 13 (76.5) 0.14
Caucasian, n (%) 111 (99.1) 24 (100.0) 71 (100.0) 16 (94.1) 0.15
BMI, kg/m2, mean (SD) 30.0 (5.6) 31.7 (5.5) 29.2 (5.6) 30.9 (5.4) 0.97
Substance use
 Tobacco, n (%)











NSAID use, n (%) 55 (49.1) 9 (37.5) 39 (54.9) 7 (41.2) 0.29
PPI use, n (%) 110 (98.2) 24 (100.0) 70 (98.6) 16 (94.1) 0.33
EGD findings
 Length of BE, cm, median (IQR)
 Erosive esophagitis, n (%)

















 Circumferential RFA, n (%)












 Follow-up, days, median (range)
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Table 3




Age, years (SD) 60.7 (13.4) 64.1 (10.8) 0.40
Male, n (%) 7 (87.5) 77 (77.8) 1.00
Caucasian, n (%) 8 (100.0) 98 (99.0) 1.00
BMI, kg/m2, mean (SD) 32.2 (4.7) 29.9 (5.8) 0.28
Substance use
 Tobacco, n (%)







NSAID use, n (%) 4 (50.0) 47 (47.5) 1.00
History of prior stricture, n (%) 1 (12.5) 6 (6.1) 0.43
EGD findings
 Length of BE, cm, median (IQR)
 Erosive esophagitis, n (%) Medium or large hiatus hernia, n (%)
 Intact Nissen fundoplication, n (%)



























EMR during treatment, n (%) 3 (37.5) 34 (34.3) 1.00
Circumferential RFA during treatment, n (%) 5 (62.5) 63 (63.6) 1.00
Erosive esophagitis during treatment, n (%) 2 (25.0) 16 (16.2) 0.62
Total treatment sessions, median (IQR) 3 (2.5-4) 3 (2-4) 0.96
RFA treatment sessions, median (IQR) 3 (2.5-3.5) 3 (2-4) 0.78
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Table 4
Prior Studies Reporting Recurrence in Patients with CE-IM After Successful RFA for Dysplastic BE







Pouw (10) 2008 43 21 5 (12%) 6.6
Gondrie (18) 2008 11 14 1 (9%) 7.8
Gondrie (19) 2008 12 9.5 0 (0%) 0.0
Pouw (12) 2010 23 22 3 (13%) 7.1
Herrero (13) 2011 19 21 (mean) 5 (26%) 15.0
van Vilsteren
(14)
2011 21 15 4 (19%) 15.2
Vaccaro (15) 2011 47 13.3 15 (32%) 28.8
Shaheen (16) 2011 108 36 14 (13%) 4.3
*
Estimate of recurrence rate calculated as (number of recurrences)/(number of patients under surveillance × median follow-up)
Am J Gastroenterol. Author manuscript; available in PMC 2013 October 28.
